| 2025-04-02 |
复牌提示：
2025-04-01 19:50:00 停牌，复牌日期 2025-04-03 00:00:01
|
| 2025-04-02 |
详情>>
内部人交易：
VAN NOSTRAND ROBERT L等共交易8笔
|
| 2025-03-20 |
详情>>
股本变动：
变动后总股本10652.16万股
|
| 2025-02-21 |
详情>>
业绩披露：
2024年年报每股收益-0.72美元,归母净利润-7467.6万美元,同比去年增长46.54%
|
| 2025-02-18 |
股东大会：
将于2025-03-27召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger (which we refer to, as it may be amended from time to time, as the “Merger Agreement”), dated January 10, 2025, by and among ITI, Johnson & Johnson, a New Jersey corporation (which we refer to as “Johnson & Johnson”), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (which we refer to as “Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into ITI (which we refer to as the “Merger”), with ITI surviving the Merger as a wholly owned subsidiary of Johnson & Johnson (we refer to this proposal as the “Merger Proposal”);
2.To consider and vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to ITI’s named executive officers that is based on or otherwise relates to the Merger and/or the other transactions contemplated by the Merger Agreement (which, together with the Merger, we refer to as the “Transactions”) (we refer to this proposal as the “Compensation Proposal”);
3.To consider and vote on a proposal to adjourn the Company Stockholders’ Meeting to a later date or dates as provided in the Merger Agreement, if necessary or appropriate, including to solicit additional votes if there are insufficient votes to adopt the Merger Agreement at the time of the Company Stockholders’ Meeting (we refer to this proposal as the “Adjournment Proposal”).
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.57美元,归母净利润-5779.1万美元,同比去年增长47.98%
|
| 2024-10-30 |
财报披露：
美东时间 2024-10-30 盘前发布财报
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-0.31美元,归母净利润-3146.7万美元,同比去年增长63.76%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.16美元,归母净利润-1524.7万美元,同比去年增长65.39%
|
| 2024-04-29 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect one director to serve a three-year term expiring in 2027;
2.To approve an amendment and restatement of the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan (the "2018 Plan") to, among other things, increase the number of shares of our common stock authorized for issuance under the 2018 Plan by 5,000,000 shares;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-1.46美元,归母净利润-1.4亿美元,同比去年增长45.49%
|
| 2024-02-22 |
详情>>
业绩披露：
2021年年报每股收益-3.5美元,归母净利润-2.84亿美元,同比去年增长-25.16%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.16美元,归母净利润-1.11亿美元,同比去年增长47.65%
|
| 2023-11-02 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.26美元,归母净利润-2.12亿美元,同比去年增长-6.98%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.91美元,归母净利润-8683.7万美元,同比去年增长45.29%
|
| 2023-05-04 |
详情>>
业绩披露：
2023年一季报每股收益-0.46美元,归母净利润-4405.3万美元,同比去年增长38.92%
|
| 2023-04-28 |
股东大会：
将于2023-06-23召开股东大会
会议内容 ▼▲
- 1.To elect one director to serve a three-year term expiring in 2026.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement.
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2023-03-01 |
详情>>
业绩披露：
2022年年报每股收益-2.72美元,归母净利润-2.56亿美元,同比去年增长9.81%
|
| 2022-04-21 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve a three-year term expiring in 2025;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
4.To approve by an advisory vote the frequency of holding an advisory vote on compensation of our named executive officers;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-21召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve a three-year term expiring in 2024;
2.To approve an amendment to Intra-Cellular Therapies, Inc.’s Restated Certificate of Incorporation to increase the number of shares of our common stock authorized for issuance from 100,000,000 to 175,000,000;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2020-04-09 |
股东大会：
将于2020-05-27召开股东大会
会议内容 ▼▲
- 1.To elect one director to serve a three-year term expiring in 2023;
2.To approve an amendment and restatement of the Intra-Cellular Therapies, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) to, among other things, increase the number of shares of our common stock authorized for issuance under the 2018 Plan by 6,500,000 shares;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-25召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2022;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-18召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2021;
2.To approve the Intra-Cellular Therapies, Inc. 2018 Equity Incentive Plan;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2017-05-01 |
股东大会：
将于2017-06-27召开股东大会
会议内容 ▼▲
- 1. To elect one director to serve a three-year term expiring in 2020;
2. To ratify the appointment of Ernst Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
4. To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-14召开股东大会
会议内容 ▼▲
- 1. To elect three directors to serve three-year terms expiring in 2019;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
4. To approve by an advisory vote the frequency of holding an advisory vote on compensation of our named executive officers;
5. To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2015-04-28 |
股东大会：
将于2015-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2018;
2.To approve amendments to the Intra-Cellular Therapies, Inc. 2013 Equity Incentive Plan (the “Plan”) to increase the number of shares of our common stock reserved for issuance under the Plan and to increase the maximum number of shares available for issuance of options, stock appreciation rights and other similar awards to any one participant in any calendar year for purposes of meeting the requirements for qualified performance-based compensation under Section 162(m) of the Internal Revenue Code;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|